Mylan acquired the non-sterile topicals-focused specialty and generics business of Renaissance Acquisition Holdings for $950M cash at closing plus contingent payments up to $50M (~$1B total). Acquired ~25 branded/generic topical products, an active pipeline of ~25 products, U.S. dermatology sales infrastructure, and integrated manufacturing. Closed June 15, 2016. ~$370M in 2015 revenues.